Back

A very short duration of dual-antiplatelet therapy following percutaneous coronary intervention: a meta-analysis of randomized clinical trials

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in acute coronary syndromes (3) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor John Sakaleros

Indiana University, Bloomington (United States of America)

6 More presentations in this session

Presentation thumbnail
Comparative effectiveness of prasugrel and ticagrelor among patients undergoing contemporary PCI: insights from the BMC2 registry
Doctor E. Dayoub (Ann Arbor, US)
Abstract Slides Video
Presentation thumbnail
Colchicine for the secondary prevention of cardiovascular diseases: a cumulative-dose meta-analysis of randomized controlled trials including 31,397 subjects worldwide
Assistant Professor Y. Chan (Hong Kong, HK)
Abstract Slides Video
Presentation thumbnail
Effect of early initiation of evolocumab on lipid profiles changes in patients with ACS Undergoing PCI (C-STAR)
Associate Professor Y. Kim (Yongin, KR)
Abstract Slides Video
Presentation thumbnail
Early TNF-alpha levels suppression by upstream evolocumab use in patients with acute myocardial infarction undergoing percutaneous coronary intervention
Doctor A. Marengo (Novara, IT)
Abstract Slides Video
Presentation thumbnail
Direct oral anticoagulants vs. vitamin K antagonists for left ventricular thrombus: a paradigm shift in antithrombotic strategy?
Doctor F. Veneziano (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in acute coronary syndromes (3)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
A shorter duration of dual-antiplatelet therapy following percutaneous coronary intervention by region of study: a meta-analysis of randomized clinical trials
thumbnail
Congress Presentation
Discussant review - DUAL-ACS
thumbnail
Congress Session
Great Debate: following an acute coronary syndrome, the default duration of dual antiplatelet therapy should be 12 months

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources